Migraine with aura from pathophysiology to treatment

Therapeutic strategies

Giovinavi D'Andrea, G. Allais, L. Grazzi, L. Fumagalli

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Migraine with aura (MwA) sufferers, at times, need specific treatments. This is the case when the auras are frequent, prolonged and cause anxiety and distress. Abnormal release of glutamate, that may trigger auras, and abnormal platelet behaviour, that constitute a possible predisposing factor to MwA, may be possible targets for MwA specific prophylactic therapy. Here we present results obtained by using lamotrigine, an agent known to inhibit glutamate release, and picotamide, an antiplatelet drug. Both drugs significantly reduced, in two open label trials, the frequency and the duration of auras. In comparison with lamotrigine, the therapy with picotamide may offer some advantages, such as the use of the therapeutical dose from the first day of treatment (lamotrigine needs one month to reach such a dose) and the possibility to prevent cerebral ischaemic events and migraine stroke, a rare but severe complication of MwA attacks.

Original languageEnglish
JournalNeurological Sciences
Volume26
Issue numberSUPPL. 2
DOIs
Publication statusPublished - May 2005

Fingerprint

Migraine with Aura
Epilepsy
Glutamic Acid
Platelet Aggregation Inhibitors
Therapeutics
Migraine Disorders
Causality
Blood Platelets
Anxiety
Stroke
Pharmaceutical Preparations
lamotrigine
picotamide

Keywords

  • Lamotrigine
  • Migraine with aura
  • Neuronal hyperexcitability
  • Picotamide
  • Platelet activation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Migraine with aura from pathophysiology to treatment : Therapeutic strategies. / D'Andrea, Giovinavi; Allais, G.; Grazzi, L.; Fumagalli, L.

In: Neurological Sciences, Vol. 26, No. SUPPL. 2, 05.2005.

Research output: Contribution to journalArticle

D'Andrea, Giovinavi ; Allais, G. ; Grazzi, L. ; Fumagalli, L. / Migraine with aura from pathophysiology to treatment : Therapeutic strategies. In: Neurological Sciences. 2005 ; Vol. 26, No. SUPPL. 2.
@article{f05eea37ee4e4e33a1733cb23830626a,
title = "Migraine with aura from pathophysiology to treatment: Therapeutic strategies",
abstract = "Migraine with aura (MwA) sufferers, at times, need specific treatments. This is the case when the auras are frequent, prolonged and cause anxiety and distress. Abnormal release of glutamate, that may trigger auras, and abnormal platelet behaviour, that constitute a possible predisposing factor to MwA, may be possible targets for MwA specific prophylactic therapy. Here we present results obtained by using lamotrigine, an agent known to inhibit glutamate release, and picotamide, an antiplatelet drug. Both drugs significantly reduced, in two open label trials, the frequency and the duration of auras. In comparison with lamotrigine, the therapy with picotamide may offer some advantages, such as the use of the therapeutical dose from the first day of treatment (lamotrigine needs one month to reach such a dose) and the possibility to prevent cerebral ischaemic events and migraine stroke, a rare but severe complication of MwA attacks.",
keywords = "Lamotrigine, Migraine with aura, Neuronal hyperexcitability, Picotamide, Platelet activation",
author = "Giovinavi D'Andrea and G. Allais and L. Grazzi and L. Fumagalli",
year = "2005",
month = "5",
doi = "10.1007/s10072-005-0420-y",
language = "English",
volume = "26",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Migraine with aura from pathophysiology to treatment

T2 - Therapeutic strategies

AU - D'Andrea, Giovinavi

AU - Allais, G.

AU - Grazzi, L.

AU - Fumagalli, L.

PY - 2005/5

Y1 - 2005/5

N2 - Migraine with aura (MwA) sufferers, at times, need specific treatments. This is the case when the auras are frequent, prolonged and cause anxiety and distress. Abnormal release of glutamate, that may trigger auras, and abnormal platelet behaviour, that constitute a possible predisposing factor to MwA, may be possible targets for MwA specific prophylactic therapy. Here we present results obtained by using lamotrigine, an agent known to inhibit glutamate release, and picotamide, an antiplatelet drug. Both drugs significantly reduced, in two open label trials, the frequency and the duration of auras. In comparison with lamotrigine, the therapy with picotamide may offer some advantages, such as the use of the therapeutical dose from the first day of treatment (lamotrigine needs one month to reach such a dose) and the possibility to prevent cerebral ischaemic events and migraine stroke, a rare but severe complication of MwA attacks.

AB - Migraine with aura (MwA) sufferers, at times, need specific treatments. This is the case when the auras are frequent, prolonged and cause anxiety and distress. Abnormal release of glutamate, that may trigger auras, and abnormal platelet behaviour, that constitute a possible predisposing factor to MwA, may be possible targets for MwA specific prophylactic therapy. Here we present results obtained by using lamotrigine, an agent known to inhibit glutamate release, and picotamide, an antiplatelet drug. Both drugs significantly reduced, in two open label trials, the frequency and the duration of auras. In comparison with lamotrigine, the therapy with picotamide may offer some advantages, such as the use of the therapeutical dose from the first day of treatment (lamotrigine needs one month to reach such a dose) and the possibility to prevent cerebral ischaemic events and migraine stroke, a rare but severe complication of MwA attacks.

KW - Lamotrigine

KW - Migraine with aura

KW - Neuronal hyperexcitability

KW - Picotamide

KW - Platelet activation

UR - http://www.scopus.com/inward/record.url?scp=20444419402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444419402&partnerID=8YFLogxK

U2 - 10.1007/s10072-005-0420-y

DO - 10.1007/s10072-005-0420-y

M3 - Article

VL - 26

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 2

ER -